Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Empagliflozin (12.5mg) + Metformin (500mg)
Therapeutic Category
Antidiabetic, ENDOCRINOLOGY and Hormonal range, Endocrinology
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
6x10
Price
₹360/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Emplozin M 12.5/500 Tablet is a combination of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Metformin, a biguanide class antidiabetic drug. This combination works synergistically to help manage Type 2 diabetes mellitus by lowering blood sugar levels. Empagliflozin works by preventing the reabsorption of glucose from the kidneys, increasing glucose excretion through urine. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, both of which contribute to better control of blood sugar.
This dual-action tablet is used in patients who cannot adequately control their blood sugar levels through diet, exercise, or single-drug therapy alone. It can be prescribed for adult patients with Type 2 diabetes as part of a comprehensive diabetes management plan, often along with diet and exercise.
May cause nausea, vomiting, diarrhea, or dehydration; rare cases of lactic acidosis.
For the management of Type 2 diabetes mellitus, used alongside diet and exercise to control blood sugar levels.
Not recommended for patients with severe kidney issues or metabolic acidosis; regular monitoring of kidney function is advised.
Store in a cool, dry place, away from direct sunlight and moisture.
Composition : Empagliflozin (12.5mg) + Metformin (1000mg)
Composition : Empagliflozin (5mg) + Metformin (500mg)
Composition : Empagliflozin (10mg) + Sitagliptin 100mg
Composition : Empagliflozin (25mg) + Sitagliptin (100mg) Tablet
Composition : Empagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg (extended release)
Composition : Empagliflozin 25mg + Sitagliptin 100mg + Metformin 1000mg (extended release)
Composition : Empagliflozin (10mg) + Linagliptin (5mg)
Composition : Empagliflozin (25mg) + Linagliptin (5mg)
Composition : Empagliflozin (25mg) Tablet
Composition : Empagliflozin (10mg) Tablet
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This anti-diabetic combination is widely used in type 2 diabetes management, making it a strong prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic control. It is commonly prescribed by diabetologists and physicians for effective dual therapy in diabetes care.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 12.5mg + Metformin 500mg Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology and general medicine segments when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.